Group B Streptococcus (GBS) is the most frequent cause of neonatal morbidity and mortality, with the highest incidence (1.21 cases per 1000 live births) observed in Africa [1] . Preterm delivery and low birth weight are risk factors associated with increased invasive GBS disease incidence in infants. In addition, maternal GBS disease and dissemination in utero may trigger premature birth, late miscarriages, and stillbirths [1] . Recently, maternal HIV infection has been shown to increase the risk of invasive GBS disease in infants with in-utero HIV exposure, even in the absence of them being HIV infected [2] .
Increased susceptibility to bacterial and viral infections in HIV-exposed uninfected (HEU) infants is partly attributable to reduced maternally derived antibodies [2, 3] . Similarly, transplacental transfer of antibodies against GBS capsular polysaccharide is lower in HIV-infected women, [4] , which might contribute to the heightened susceptibility to invasive GBS disease amongs HEU infants [2] . Hypergammaglobulinaemia, a common feature among HIV-infected individuals, has been proposed as a possible mechanism whereby Fc receptors (FcRn) on maternofetal syncytiotrophoblast that are essential in transporting IgG across the placenta are saturated by nonspecific antibodies, resulting in reduced transplacental transfer of antibodies [5] .
Considering that protein antigens induce antibodies that are preferentially transported by FcRn [6] , maternal HIV infection could affect the transplacental transfer of antibodies targeted at GBS surface proteins. The pangenome sequence of GBS consists of 396 conserved genes encoding surface-associated proteins, and a further 193 genes encoding variable-surface proteins [7] , for which virulence characteristics and immunogenicity have only been described for a few. The aim of this study was to investigate the relationship between HIV infection and transplacental transfer of naturally occurring antibodies directed against 8 GBS surface proteins previously identified using computational algorithms [8] .
METHODS

Study Population
Serum samples from mother-newborn pairs (who were previously recruited to participate in a study to evaluate the effects of maternal HIV infection on transplacental transfer of antibodies to GBS polysaccharide and pilus island epitopes) were analyzed [4] . Briefly, 164 women with confirmed HIV status during pregnancy, who delivered infants at ≥ 36 weeks' gestation age and birth weight of ≥ 2500 grams were enrolled. GBS colonization amongs the women was confirmed by a positive growth culture of lower vaginal and rectal swab using selective media as described [4] . Serum samples taken from maternal and cord blood was stored at -70ºC until analyzed for this study.
Purification of Recombinant Proteins
Genes for GBS surface proteins gbs0392, gbs0393, gbs1356, gbs1539, gbs2106, Sip, and Foldase PsrA (gbs2107) were cloned from serotype III NEM316 strain into pETite vector (Lucigen, Middleton, WI). Cloned vectors were transformed into an Escherichia coli BL21 strain for protein production. Proteins were affinity purified in immobilized Ni 2+ ion-affinity columns using 500 mM imidazole, 0.5 M NaCl, and 20 mM phosphate buffer solution, and stored in 50% glycerol at -70ºC. Prior to performing immunological analysis, proteins were desalted using PD-10 desalting columns (GE Healthcare, Germany) as per manufacturer's instructions.
Quantification of Antibody Titers to GBS Surface Proteins
Unique microbead regions (Bio-Rad, Hercules, CA) were bound with 50 µg/ml of protein using a 2-step carbodiimide reaction [9] . The protein-coupled beads were blocked with phosphate-buffer saline, 10% fetal bovine serum, and 0.05% NaN 3 , and stored in the dark at -4°C. Multiplex Luminex assay was performed as previously reported [8] . Immunoglobulin G (IgG) titers of paired maternal and cord serum samples were measured simultaneously. Serum IgG titers were measured in duplicates of 1:200 dilutions. Polygam (adult pooled IgG; National Bioproducts, South Africa) was used as a reference serum and assigned 100 arbitrary units per milliliter per antigen. IgG titers were extrapolated for each antigen and reported as units/mL (U/mL). Two controls were included in each immunoassay that consisted of pools of high-and low-titer serum samples from HIV-uninfected pregnant women. Participants with antibody levels below the detection limit were assigned a value one-quarter of the lower limit of detection.
Statistical Analysis
Data analysis was performed using STATA software (version 13.1, Stata Corp, College Station, TX) and GraphPad Prism (version 5.03, GraphPad Software, San Diego, CA). Maternal and cord antibody titers were log 10 -transformed for parametric statistical comparisons. Differences in geometric mean titer (GMT) between HIV-uninfected and HIV-infected mothers at delivery together with the respective GMT between HIVunexposed and HEU newborns were tested with a 2-tailed Student t test. A P value < .05 was considered statistically significant after adjusting for GBS colonization, maternal age, gestational age and parity using multivariate regression.
Cord-maternal antibody ratios were calculated for each mother-newborn dyad to evaluate the effect of HIV infection on transplacental transfer of antibodies. Quantile regression was used to compare median ratios between HIV-uninfected and HIV-infected mother-newborn dyad, and adjusted for GBS colonization, colonizing serotype, maternal age, gestational age, and parity. Furthermore, a percentage difference in cord-maternal antibody ratios (CMRs) was calculated as (1 -CMR HIV+ / CMR HIV-) × 100% to measure the relative efficiency of transplacental antibody transfer between HIV-infected compared to HIV-uninfected women. Among HIV-infected mothers, the correlation between maternal antibody titers and maternal CD4 + lymphocyte count and HIV-1 viral load was measured using univariate quantile regression.
All participants in the original study signed informed consent forms. This study was approved by the Human Research Ethics Committee of the University of the Witwatersrand (Approval number: M140902), who granted a waiver of further consent for the additional testing of the archived samples.
RESULTS
A total of 164 mother-newborn dyads were analyzed in this study. Detailed demographic information about the study participants is shown in Supplementary Table S1 [4] . Briefly, of the 164 mothers, 81 were HIV uninfected and 83 were HIV infected. CD4 + lymphocyte counts were available for 71 (85.5%) of the 83 HIV-infected women, with a median of 423 cells/µL (range, 46-1268 cells/µL). HIV-1 RNA viral loads were detected in 79 HIV-infected women with a median of 96 copies/mL (range, 20-146 055 copies/mL). Using vaginal and rectal swabs, positive GBS growth at delivery were detected in 29.9% (49 of 164) women, including among 27.2% (22 of 81) HIV-uninfected and 32.5% (27 of 83; P = .45) HIV-infected women (Supplementary Table S1 ). Serotype distribution did not differ by HIV status, with the frequently colonizing serotypes being Ia (40.8%), III (28.6%), V (18.4%), II (8.2%), and Ib (4.1%) [4] .
Maternal Antibodies to GBS Surface Proteins
All maternal serum samples had detectable antibody titers for the analyzed GBS surface proteins. IgG GMT against the GBS surface proteins analyzed did not differ by GBS colonization status among the women (Supplementary Table S2 ). HIV-infected women had lower antibody GMT (U/mL) compared to HIV-uninfected women, including after adjusting for cofactor variables, for proteins Sip (132.42 vs 186.72; P = .002), Foldase (162.06 vs 220.82; P = .035), and other putative proteins, including gbs2106 (153.62 vs 235.11; P = .002), gbs0393 (258.97 vs 381.35; P = .001), and gbs1356 (156.36 vs 215.49; P = .035) (Figure 1 ). Similar trends were observed for gbs0392 and gbs1539, with antibody GMT being higher among HIVuninfected compared to HIV-infected women, albeit not statistically significant. No significant correlation was observed between CD4
+ lymphocyte count and HIV-1 RNA viral load with maternal antibody titers for all the GBS surface proteins (Supplementary Table S3 and S4).
Infant Antibodies to GBS Surface Proteins
Of the 164 cord serum samples analyzed, 18 samples had antibody titers below the detection limit for gbs1539, 2 had no detectable titers to gbs1539 and gbs0392, and 1 had no detectable titres for gbs1539, gbs0393, Sip and gbs1356. Antibody GMT in HEU newborns (n = 83) were significantly lower compared to HIV-unexposed newborns (n = 81) for all proteins after multivariate regression controlling for cofactor variables, including for Sip (80.37 vs 153.70; P < .0001), Foldase (71.07 vs 142.27; P < .0001), BibA (127.46 vs180.42; P = .026), gbs2106 (82.91 vs 205.83; P < .0001), gbs0393 (113.50 vs 241.33; P < .0001), gbs1539 (73.12 vs 138.38; P = .016), gbs1356 (55.05 vs 104.06; P = .001), and gbs0392 (81.70 vs 130.2; P < .0001) (Figure 1 ).
Effects of HIV Infection on Transplacental Transfer of Antibodies
Maternal antibody titers correlated positively with cord antibody titers for all GBS surface proteins, R 2 ≥ 0.5 and P < .0001. Cord-maternal antibody ratios were compared between HIVinfected and HIV-uninfected mother-newborn dyads using quantile regression and adjusted for cofactor variables. Maternal HIV infection was associated with lower ratios of transplacental transfer of antibodies for Sip (25.8%; P < .001), Foldase (30.4%; P < .001), gba0392 (36.5%; P = .006), gbs0393 (32.9%; P < .001), gbs1539 (39.2%; P < .008), gbs2106 (35.7%; P < .001), and BibA (19.4%; P = .004) ( Table 1 ). Antibodies to proteins gbs1539 and gbs0392 had ≤0.40 median cord-maternal antibody ratios, irrespective of maternal HIV infection. No correlation was observed between cord-maternal antibody ratios with the maternal CD4 + lymphocyte count and HIV-1 RNA viral loads (Supplementary  Table S5 and S6).
DISCUSSION
In our study, we observed a 19%-39% reduction in the concentration of transplacental transfer GBS surface protein antibodies in HIV-infected compared to HIV-uninfected mother-newborn dyads. Low antibody GMT in HIV-infected mothers together with reduced efficiency of transplacental transfer of antibodies resulted in lower antibody GMT in HEU infants compared to HIV-unexposed infants. The results of this study are similar to that reported for antibody against Haemophilus influenzae type b, Bordetella pertussis, tetanus, and Streptococcus pneumoniae in HIV-infected mother-newborns [3] . A reduction in transplacental transfer of antibodies against GBS capsular polysaccharide for the predominantly invasive serotypes Ia, II, III, and V has been noted previously [4] . Maternally derived antibodies against these invasive serotypes play an important role in providing protection to infants [10] . It is therefore likely that the impediment of maternofetal antibody transfer against GBS surface proteins together with antibodies against GBS capsular polysaccharide (CPS) during intrauterine HIV exposure may, in part, contribute to the increased risk of developing invasive GBS disease in infants.
The GBS surface proteins Sip and BibA have been previously reported to confer protection in newborn pups challenged with a lethal dose of GBS, when born to mice dams immunized with the respective protein [11, 12] . The virulence and immunological role of the other evaluated GBS proteins are unknown, as these proteins were identified computationally; however, these proteins have emerged in other studies as potential GBS virulence factors. Using subtractive DNA hybridization, gbs1356 and gbs0393 were shown to be homologous to a family of adhesion proteins that play a role in the binding of GBS to host epithelial cells [13] .
IgG 1 , primarily induced by protein antigens, is efficiently transported across the placenta compared to IgG 2 induced by CPS. Therefore, maternal immunization using a protein-based vaccine might result in higher transplacental transfer of antibody concentrations to provide protection against invasive GBS disease in newborns [6] . Considerations, however, should be taken in selecting highly immunogenic protein antigens that are capable of crossing the placenta and provide protection to both the mother and the infant. Antibodies to the highly conserved proteins such as Sip (expressed by all GBS isolates), BibA (that exist in 3 different allelic forms [12] ), and gbs2106 protein were efficiently transferred across the placenta in the absence of maternal HIV infection.
The prevalence of GBS colonization in HIV-infected women is similar to HIV-uninfected women, including for countries where there is a higher burden of HIV infection [14] and as observed in our study population. Antibody GMT did not differ by colonization status or colonizing serotype among HIV-uninfected and HIV-infected mothers for the investigated GBS surface protein antigens. Acquisition of GBS colonization occurs frequently during pregnancy [14] ; therefore, the difference in the IgG level that may result from GBS colonization cannot be detected using a cross-sectional study [15] . Other limitations of the study include use of Polygam (National Bioproducts, South Africa) as reference serum, which does not allow quantification of absolute antibody concentrations comparable to other study populations.
Given that HEU infants are at high risk of invasive GBS due to reduced maternally derived antibodies, increasing maternal antibodies by vaccination has the potential to reduce the risk of invasive GBS disease. HIV-infected women, however, were reported to have lower antibody concentrations specific to CPS following immunization with a polysaccharide-protein glycoconjugate-based vaccine [10] . The poor immunogenic response in HIV-infected women may be circumvented by either adapting an alternate dosing schedule or dosing strength, or substituting for a GBS surface protein. Because it appears that the antibody response induced by proteins Sip, gbs2106, gbs1356, gbs0393, and Foldase are attenuated by HIV infection, this might contribute to the increased susceptibility to invasive GBS disease in HEU infants; therefore, further investigations are required to assess the potential inclusion of these proteins as vaccine candidates for protection against invasive GBS disease.
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